{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:27:42Z","timestamp":1788280062958,"version":"build-2803163510"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hong Kong General Research Fund","award":["12102722, 12104825, and 12106424"],"award-info":[{"award-number":["12102722, 12104825, and 12106424"]}]},{"name":"the Hong Kong RGC Theme-based Research Scheme","award":["T12-201\/20-R"],"award-info":[{"award-number":["T12-201\/20-R"]}]},{"name":"Shenzhen Medical Research Fund","award":["B2502016"],"award-info":[{"award-number":["B2502016"]}]},{"name":"the National Key R&D Program of China","award":["2024YFC3506200 and 2024YFC3506205"],"award-info":[{"award-number":["2024YFC3506200 and 2024YFC3506205"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation Council of China","doi-asserted-by":"crossref","award":["82472394 and 82172386"],"award-info":[{"award-number":["82472394 and 82172386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Science and Technology Program","award":["SGDX20240115112400001"],"award-info":[{"award-number":["SGDX20240115112400001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00981-5","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:05:01Z","timestamp":1786467901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment"],"prefix":"10.1186","volume":"14","author":[{"given":"Shikai","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"981_CR1","doi-asserted-by":"publisher","first-page":"105806","DOI":"10.1016\/j.phrs.2021.105806","volume":"172","author":"R Roskoski","year":"2021","unstructured":"Roskoski R. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacol Res. 2021;172:105806.","journal-title":"Pharmacol Res"},{"key":"981_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","volume":"14","author":"K Chen","year":"2021","unstructured":"Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol OncolJ Hematol Oncol. 2021;14:116.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"981_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature25459","volume":"554","author":"S Mueller","year":"2018","unstructured":"Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554:62\u20138.","journal-title":"Nature"},{"key":"981_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: Recent progress and new approaches. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:1101\u201310.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"981_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20:143.","journal-title":"Mol Cancer"},{"issue":"26","key":"981_CR6","first-page":"00519","volume":"S0092\u20138674","author":"X Wang","year":"2026","unstructured":"Wang X, Zhang Y, Lu M, Gong Y, Guan T, Hou G, et al. Farnesylation-driven KRAS phase separation promotes colon tumor growth. Cell. 2026;S0092\u20138674(26):00519\u20132.","journal-title":"Cell"},{"key":"981_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: From undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.","journal-title":"Signal Transduct Target Ther"},{"key":"981_CR8","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res MCR. 2015;13:1325\u201335.","journal-title":"Mol Cancer Res MCR"},{"key":"981_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"981_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"981_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"981_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"981_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: Resistance drivers and combinatorial strategies. Trends Cancer. 2025;11:91\u2013116.","journal-title":"Trends Cancer"},{"key":"981_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-025-02364-0","volume":"24","author":"X Wang","year":"2025","unstructured":"Wang X, Wu J, Xiao A, Wang J, Tian J. Evolution of direct RAS inhibitors: From undruggable target to clinical breakthroughs. Mol Cancer. 2025;24:229.","journal-title":"Mol Cancer"},{"key":"981_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12672-024-01455-6","volume":"15","author":"PS Ramalingam","year":"2024","unstructured":"Ramalingam PS, Premkumar T, Sundararajan V, Hussain MS, Arumugam S. Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches. Discov Oncol. 2024;15:592.","journal-title":"Discov Oncol"},{"key":"981_CR16","doi-asserted-by":"publisher","first-page":"e70401","DOI":"10.1002\/mco2.70401","volume":"6","author":"G Fan","year":"2025","unstructured":"Fan G, Chen S, Zhang Q, Yu N, Shen Z, Liu Z, et al. Proteolysis-targeting chimera (PROTAC): Current applications and future directions. MedComm. 2025;6:e70401.","journal-title":"MedComm"},{"key":"981_CR17","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130:5976\u201388.","journal-title":"J Clin Invest"},{"key":"981_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498\u2013503.","journal-title":"Nature"},{"key":"981_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/349117a0","volume":"349","author":"HR Bourne","year":"1991","unstructured":"Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: Conserved structure and molecular mechanism. Nature. 1991;349:117\u201327.","journal-title":"Nature"},{"key":"981_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","volume":"18","author":"T Pantsar","year":"2019","unstructured":"Pantsar T. The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J. 2019;18:189\u201398.","journal-title":"Comput Struct Biotechnol J"},{"key":"981_CR21","doi-asserted-by":"publisher","first-page":"15500","DOI":"10.1073\/pnas.0504114102","volume":"102","author":"SJ Plowman","year":"2005","unstructured":"Plowman SJ, Muncke C, Parton RG, Hancock JF. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc Natl Acad Sci U S A. 2005;102:15500\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR22","doi-asserted-by":"publisher","first-page":"e2014605118","DOI":"10.1073\/pnas.2014605118","volume":"118","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Prakash PS, Liang H, Gorfe AA, Hancock JF. The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure. Proc Natl Acad Sci U S A. 2021;118:e2014605118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR23","doi-asserted-by":"publisher","first-page":"eadj4137","DOI":"10.1126\/sciadv.adj4137","volume":"10","author":"MJ Whitley","year":"2024","unstructured":"Whitley MJ, Tran TH, Rigby M, Yi M, Dharmaiah S, Waybright TJ, et al. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties. Sci Adv. 2024;10:eadj4137.","journal-title":"Sci Adv"},{"key":"981_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1021\/acscentsci.7b00440","volume":"4","author":"X Zhang","year":"2018","unstructured":"Zhang X, Cao J, Miller SP, Jing H, Lin H. Comparative nucleotide-dependent interactome analysis reveals shared and differential properties of KRas4a and KRas4b. ACS Cent Sci Am Chem Soc. 2018;4:71\u201380.","journal-title":"ACS Cent Sci Am Chem Soc"},{"key":"981_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JML Ostrem","year":"2016","unstructured":"Ostrem JML, Shokat KM. Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15:771\u201385.","journal-title":"Nat Rev Drug Discov"},{"key":"981_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543\u201350.","journal-title":"Cancer Cell"},{"key":"981_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.trecan.2017.01.007","volume":"3","author":"R Nussinov","year":"2017","unstructured":"Nussinov R, Wang G, Tsai C-J, Jang H, Lu S, Banerjee A, et al. Calmodulin and PI3K signaling in KRAS cancers. Trends Cancer. 2017;3:214\u201324.","journal-title":"Trends Cancer"},{"key":"981_CR28","doi-asserted-by":"publisher","first-page":"105110","DOI":"10.1016\/j.compbiomed.2021.105110","volume":"141","author":"M Gerber","year":"2022","unstructured":"Gerber M, Goel S, Maitra R. In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-loop, switch I&II regions preventing GTP hydrolysis. Comput Biol Med. 2022;141:105110.","journal-title":"Comput Biol Med"},{"key":"981_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/2159-8290.CD-21-1494","volume":"12","author":"DK Simanshu","year":"2022","unstructured":"Simanshu DK, Morrison DK. A structure is worth a thousand words: New insights for RAS and RAF regulation. Cancer Discov. 2022;12:899\u2013912. 4.","journal-title":"Cancer Discov"},{"key":"981_CR30","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1021\/acs.chemrev.8b00467","volume":"119","author":"MD Paul","year":"2019","unstructured":"Paul MD, Hristova K. The RTK interactome: Overview and perspective on RTK heterointeractions. Chem Rev. 2019;119:5881\u2013921.","journal-title":"Chem Rev"},{"key":"981_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/363085a0","volume":"363","author":"N Li","year":"1993","unstructured":"Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to ras signalling. Nature. 1993;363:85\u20138.","journal-title":"Nature"},{"key":"981_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0092-8674(92)90167-B","volume":"70","author":"EJ Lowenstein","year":"1992","unstructured":"Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992;70:431\u201342.","journal-title":"Cell"},{"key":"981_CR33","doi-asserted-by":"crossref","unstructured":"Kazemein Jasemi NS, Reza Ahmadian M. Allosteric regulation of GRB2 modulates RAS activation. Small GTPases. 2022;13:282\u20136.","DOI":"10.1080\/21541248.2022.2089001"},{"key":"981_CR34","doi-asserted-by":"publisher","first-page":"FFacultyRev1000","DOI":"10.12688\/f1000research.14143.1","volume":"7","author":"A Zinkle","year":"2018","unstructured":"Zinkle A, Mohammadi M. A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. F1000Research. 2018;7:FFacultyRev1000\u2013872.","journal-title":"F1000Research"},{"key":"981_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/27938","volume":"394","author":"G Tzivion","year":"1998","unstructured":"Tzivion G, Luo Z, Avruch J. A dimeric 14-3-3 protein is an essential cofactor for raf kinase activity. Nature. 1998;394:88\u201392.","journal-title":"Nature"},{"key":"981_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00018-010-0520-6","volume":"68","author":"CM Udell","year":"2010","unstructured":"Udell CM, Rajakulendran T, Sicheri F, Therrien M. Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci CMLS. 2010;68:553\u201365.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"981_CR37","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41467-021-21422-x","volume":"12","author":"TH Tran","year":"2021","unstructured":"Tran TH, Chan AH, Young LC, Bindu L, Neale C, Messing S, et al. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun Nat Publishing Group. 2021;12:1176.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"981_CR38","doi-asserted-by":"publisher","first-page":"a033746","DOI":"10.1101\/cshperspect.a033746","volume":"9","author":"EM Terrell","year":"2019","unstructured":"Terrell EM, Morrison DK. Ras-mediated activation of the raf family kinases. Cold Spring Harb Perspect Med. 2019;9:a033746.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"981_CR39","doi-asserted-by":"publisher","first-page":"E10576","DOI":"10.1073\/pnas.1720352115","volume":"115","author":"LC Young","year":"2018","unstructured":"Young LC, Hartig N, Boned Del R\u00edo I, Sari S, Ringham-Terry B, Wainwright JR, et al. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to noonan syndrome pathogenesis. Proc Natl Acad Sci U S A. 2018;115:E10576\u201385.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","volume":"10","author":"Y Song","year":"2023","unstructured":"Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis. 2023;10:76\u201388.","journal-title":"Genes Dis"},{"key":"981_CR41","first-page":"1997","volume":"19","author":"Y-J Guo","year":"2020","unstructured":"Guo Y-J, Pan W-W, Liu S-B, Shen Z-F, Xu Y. Hu L-L. ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997\u20132007.","journal-title":"Exp Ther Med"},{"key":"981_CR42","doi-asserted-by":"crossref","unstructured":"Dong Chen SB, Holt KH, Pessin JE. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem. 1996;271:6328\u201332.","DOI":"10.1074\/jbc.271.11.6328"},{"key":"981_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K\/AKT signalling pathway and cancer. Gene. 2019;698:120\u20138.","journal-title":"Gene"},{"key":"981_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonz\u00e1lez-Bar\u00f3n M. PI3K\/akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193\u2013204.","journal-title":"Cancer Treat Rev"},{"key":"981_CR45","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101:1371\u2013426.","journal-title":"Physiol Rev"},{"key":"981_CR46","doi-asserted-by":"publisher","first-page":"20367","DOI":"10.1038\/s41598-025-08345-z","volume":"15","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee S, Wolan MJ, Scott MK, Riley VA, Sokolov AM, Feliciano DM. A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model. Sci Rep. 2025;15:20367.","journal-title":"Sci Rep"},{"key":"981_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.117.014415","volume":"70","author":"C Yan","year":"2018","unstructured":"Yan C, Theodorescu D. RAL GTPases: Biology and potential as therapeutic targets in cancer. Pharmacol Rev. 2018;70:1\u201311.","journal-title":"Pharmacol Rev"},{"key":"981_CR48","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.bbamcr.2014.09.004","volume":"1843","author":"LR Gentry","year":"2014","unstructured":"Gentry LR, Martin TD, Reiner DJ, Der CJ. Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. Biochim Biophys Acta. 2014;1843:2976\u201388.","journal-title":"Biochim Biophys Acta"},{"key":"981_CR49","doi-asserted-by":"publisher","first-page":"13406","DOI":"10.1074\/jbc.C000085200","volume":"275","author":"JF Rebhun","year":"2000","unstructured":"Rebhun JF, Chen H, Quilliam LA. Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase ral. J Biol Chem. 2000;275:13406\u201310.","journal-title":"J Biol Chem"},{"key":"981_CR50","doi-asserted-by":"publisher","first-page":"22851","DOI":"10.1074\/jbc.M115.656710","volume":"290","author":"LR Gentry","year":"2015","unstructured":"Gentry LR, Nishimura A, Cox AD, Martin TD, Tsygankov D, Nishida M, et al. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of ral GTPases. J Biol Chem. 2015;290:22851\u201361.","journal-title":"J Biol Chem"},{"key":"981_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1128\/MCB.00916-08","volume":"30","author":"K-H Lim","year":"2010","unstructured":"Lim K-H, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, et al. Aurora-a phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol. 2010;30:508\u201323.","journal-title":"Mol Cell Biol"},{"key":"981_CR52","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1158\/0008-5472.CAN-10-0952","volume":"70","author":"H Wang","year":"2010","unstructured":"Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res. 2010;70:8760\u20139.","journal-title":"Cancer Res"},{"key":"981_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0014-5793(03)00435-6","volume":"546","author":"AE Mertens","year":"2003","unstructured":"Mertens AE, Roovers RC, Collard JG. Regulation of Tiam1-rac signalling. FEBS Lett. 2003;546:11\u20136.","journal-title":"FEBS Lett"},{"key":"981_CR54","doi-asserted-by":"publisher","first-page":"13864","DOI":"10.1074\/jbc.M700505200","volume":"282","author":"DFJ Ceccarelli","year":"2007","unstructured":"Ceccarelli DFJ, Blasutig IM, Goudreault M, Li Z, Ruston J, Pawson T, et al. Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9. J Biol Chem. 2007;282:13864\u201374.","journal-title":"J Biol Chem"},{"key":"981_CR55","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1038\/ncomms5080","volume":"5","author":"J Viaud","year":"2014","unstructured":"Viaud J, Lagarrigue F, Ramel D, Allart S, Chicanne G, Ceccato L, et al. Phosphatidylinositol 5-phosphate regulates invasion through binding and activation of Tiam1. Nat Commun. 2014;5:4080.","journal-title":"Nat Commun"},{"key":"981_CR56","doi-asserted-by":"publisher","first-page":"122510","DOI":"10.1016\/j.lfs.2024.122510","volume":"342","author":"C Bailly","year":"2024","unstructured":"Bailly C, Degand C, Laine W, Sauzeau V, Kluza J. Implication of Rac1 GTPase in molecular and cellular mitochondrial functions. Life Sci. 2024;342:122510.","journal-title":"Life Sci"},{"key":"981_CR57","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.trecan.2020.02.021","volume":"6","author":"AC Cannon","year":"2020","unstructured":"Cannon AC, Uribe-Alvarez C, Chernoff J. RAC1 as a therapeutic target in malignant melanoma. Trends Cancer. 2020;6:478\u201388.","journal-title":"Trends Cancer"},{"key":"981_CR58","doi-asserted-by":"publisher","first-page":"e2305684120","DOI":"10.1073\/pnas.2305684120","volume":"120","author":"D Song","year":"2023","unstructured":"Song D, Hu F, Huang C, Lan J, She X, Zhao C, et al. Tiam1 methylation by NSD2 promotes Rac1 signaling activation and colon cancer metastasis. Proc Natl Acad Sci U S A. 2023;120:e2305684120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2011.12.006","volume":"21","author":"J Ling","year":"2012","unstructured":"Ling J, Kang Y, Zhao R, Xia Q, Lee D-F, Chang Z, et al. KrasG12D-induced IKK2\/\u03b2\/NF-\u03baB activation by IL-1\u03b1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105\u201320.","journal-title":"Cancer Cell"},{"key":"981_CR60","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1073\/pnas.1311500111","volume":"111","author":"M Martins","year":"2014","unstructured":"Martins M, McCarthy A, Baxendale R, Guichard S, Magno L, Kessaris N, et al. Tumor suppressor role of phospholipase C epsilon in ras-triggered cancers. Proc Natl Acad Sci U S A. 2014;111:4239\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR61","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7150\/jca.17779","volume":"8","author":"A Tyutyunnykova","year":"2017","unstructured":"Tyutyunnykova A, Telegeev G, Dubrovska A. The controversial role of phospholipase C epsilon (PLC\u03b5) in cancer development and progression. J Cancer. 2017;8:716\u201329.","journal-title":"J Cancer"},{"key":"981_CR62","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39:1029\u201338.","journal-title":"Cancer Metastasis Rev"},{"key":"981_CR63","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.7150\/thno.42325","volume":"10","author":"Q Gao","year":"2020","unstructured":"Gao Q, Ouyang W, Kang B, Han X, Xiong Y, Ding R, et al. Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR\/Cas9 induces efficient tumor regression. Theranostics. 2020;10:5137\u201353.","journal-title":"Theranostics"},{"key":"981_CR64","doi-asserted-by":"crossref","unstructured":"Bannoura SF, Khan HY, Azmi AS. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Front Oncol. 2022;12:1013902.","DOI":"10.3389\/fonc.2022.1013902"},{"key":"981_CR65","first-page":"333","volume-title":"The ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic ras mutants","author":"K Scheffzek","year":"1997","unstructured":"Scheffzek K, Ahmadian MR, Kabsch W, Wiesm\u00fcller L, Lautwein A, Schmitz F, et al. The ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic ras mutants. Volume 277. New York, N.Y.: Science; 1997. pp. 333\u20138."},{"key":"981_CR66","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"981_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","volume":"10","author":"GA Hobbs","year":"2020","unstructured":"Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, et al. Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 2020;10:104\u201323.","journal-title":"Cancer Discov"},{"key":"981_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/his.12021","volume":"62","author":"C Serrano","year":"2013","unstructured":"Serrano C, Simonetti S, Hern\u00e1ndez-Losa J, Valverde C, Carrato C, Bagu\u00e9 S, et al. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Histopathology. 2013;62:499\u2013504.","journal-title":"Histopathology"},{"key":"981_CR69","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","volume":"12","author":"C Johnson","year":"2022","unstructured":"Johnson C, Burkhart DL, Haigis KM. Classification of KRAS activating mutations and the implications for therapeutic intervention. Cancer Discov. 2022;12:913\u201323.","journal-title":"Cancer Discov"},{"key":"981_CR70","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jnci\/djr523","volume":"104","author":"NT Ihle","year":"2012","unstructured":"Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. JNCI J Natl Cancer Inst. 2012;104:228\u201339.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"981_CR71","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer. 2023;4:812\u201328.","journal-title":"Nat Cancer"},{"key":"981_CR72","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gutjnl-2012-302423","volume":"62","author":"S Tian","year":"2013","unstructured":"Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62:540\u20139.","journal-title":"Gut"},{"key":"981_CR73","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","volume":"12","author":"JH Cook","year":"2021","unstructured":"Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun Nat Publishing Group. 2021;12:1808.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"981_CR74","first-page":"NA","volume":"7","author":"M Cefal\u00ec","year":"2021","unstructured":"Cefal\u00ec M, Epistolio S, Palmarocchi MC, Frattini M, Dosso SD, OAE Publishing Inc. Research progress on KRAS mutations in colorectal cancer. J Cancer Metastasis Treat. 2021;7:NA\u2013NA.","journal-title":"J Cancer Metastasis Treat"},{"key":"981_CR75","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4161\/cbt.28550","volume":"15","author":"JHM Tong","year":"2014","unstructured":"Tong JHM, Lung RWM, Sin FMC, Law PPY, Kang W, Chan AWH, et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther. 2014;15:768\u201376.","journal-title":"Cancer Biol Ther"},{"key":"981_CR76","doi-asserted-by":"publisher","first-page":"104639","DOI":"10.1016\/j.compbiomed.2021.104639","volume":"135","author":"J Chen","year":"2021","unstructured":"Chen J, Wang L, Wang W, Sun H, Pang L, Bao H. Conformational transformation of switch domains in GDP\/K-ras induced by G13 mutants: An investigation through gaussian accelerated molecular dynamics simulations and principal component analysis. Comput Biol Med. 2021;135:104639.","journal-title":"Comput Biol Med"},{"key":"981_CR77","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.celrep.2019.07.026","volume":"28","author":"CW Johnson","year":"2019","unstructured":"Johnson CW, Lin Y-J, Reid D, Parker J, Pavlopoulos S, Dischinger P, et al. Isoform-specific destabilization of the active site reveals a molecular mechanism of intrinsic activation of KRas G13D. Cell Rep. 2019;28:1538\u2013e15507.","journal-title":"Cell Rep"},{"key":"981_CR78","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ccell.2018.09.002","volume":"34","author":"I Yen","year":"2018","unstructured":"Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, et al. Pharmacological induction of RAS-GTP confers RAF inhibitor sensitivity in KRAS mutant tumors. Cancer Cell. 2018;34:611\u2013e6257.","journal-title":"Cancer Cell"},{"key":"981_CR79","first-page":"23","volume":"7","author":"SS Kumar","year":"2014","unstructured":"Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE. KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest Cancer Res GCR. 2014;7:23\u20136.","journal-title":"Gastrointest Cancer Res GCR"},{"key":"981_CR80","doi-asserted-by":"publisher","first-page":"22122","DOI":"10.1073\/pnas.1908353116","volume":"116","author":"D Rabara","year":"2019","unstructured":"Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, et al. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proc Natl Acad Sci U S A. 2019;116:22122\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR81","doi-asserted-by":"publisher","first-page":"eabn2694","DOI":"10.1126\/scisignal.abn2694","volume":"15","author":"MV Huynh","year":"2022","unstructured":"Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, et al. Functional and biological heterogeneity of KRASQ61 mutations. Sci Signal. 2022;15:eabn2694.","journal-title":"Sci Signal"},{"key":"981_CR82","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1073\/pnas.0912226107","volume":"107","author":"G Buhrman","year":"2010","unstructured":"Buhrman G, Holzapfel G, Fetics S, Mattos C. Allosteric modulation of ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A. 2010;107:4931\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR83","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/2767-9764.CRC-25-0281","volume":"5","author":"RA Burge","year":"2025","unstructured":"Burge RA, Bialousow L, McFall T, Bamonte L, Johnson G, Smith M, et al. Pancreatic cells are resistant to KRASQ61L expression due to hyperactive ERK\/MAPK signaling and apoptosis induction. Cancer Res Commun. 2025;5:1865\u201378.","journal-title":"Cancer Res Commun"},{"key":"981_CR84","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1158\/0008-5472.CAN-20-0448","volume":"80","author":"Z-W Zhou","year":"2020","unstructured":"Zhou Z-W, Ambrogio C, Bera AK, Li Q, Li X-X, Li L, et al. KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Cancer Res. 2020;80:3719\u201331.","journal-title":"Cancer Res"},{"key":"981_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41698-025-01087-1","volume":"9","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Mai G, Zhao X, Tang M, Yang P, Cheng Q, et al. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: Insights from multi-cohort analysis. Npj Precis Oncol Nat Publishing Group. 2025;9:299.","journal-title":"Npj Precis Oncol Nat Publishing Group"},{"key":"981_CR86","doi-asserted-by":"publisher","first-page":"e70168","DOI":"10.1002\/cam4.70168","volume":"13","author":"X-G Wu","year":"2024","unstructured":"Wu X-G, Liu W, Wang Y-Y, Wang K, Xing B-C. Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy. Cancer Med. 2024;13:e70168.","journal-title":"Cancer Med"},{"key":"981_CR87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495\u2013509.","journal-title":"Nat Rev Cancer"},{"key":"981_CR88","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","volume":"24","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:334\u201340.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR89","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"981_CR90","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12885-024-12776-8","volume":"24","author":"Y Tang","year":"2024","unstructured":"Tang Y, Fan Y, Combined KRAS. TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis. BMC Cancer. 2024;24:1155.","journal-title":"BMC Cancer"},{"key":"981_CR91","doi-asserted-by":"publisher","first-page":"22175","DOI":"10.18632\/oncotarget.14549","volume":"8","author":"L Du","year":"2017","unstructured":"Du L, Kim JJ, Shen J, Chen B, Dai N. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: A meta-analysis. Oncotarget. 2017;8:22175\u201386.","journal-title":"Oncotarget"},{"key":"981_CR92","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.3390\/jcm14145135","volume":"14","author":"L Motta","year":"2025","unstructured":"Motta L, Molinari F, Pankovics J, Pedrazzini B, Valera A, Epistolio S, et al. Prognostic impact of KRAS-TP53 co-mutations in patients with early-stage non-small cell lung cancer: A single-center retrospective study. J Clin Med. 2025;14:5135.","journal-title":"J Clin Med"},{"key":"981_CR93","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.xcrm.2024.101578","volume":"5","author":"K Fukuda","year":"2024","unstructured":"Fukuda K, Takeuchi S, Arai S, Nanjo S, Sato S, Kotani H, et al. Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell Rep Med. 2024;5:101578.","journal-title":"Cell Rep Med"},{"key":"981_CR94","doi-asserted-by":"publisher","first-page":"175883592110069","DOI":"10.1177\/17588359211006950","volume":"13","author":"M Gu","year":"2021","unstructured":"Gu M, Xu T, Chang P. KRAS\/LKB1 and KRAS\/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol. 2021;13:17588359211006950.","journal-title":"Ther Adv Med Oncol"},{"key":"981_CR95","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234\u20138.","journal-title":"Nature"},{"key":"981_CR96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/187152012799014968","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T. Are KRAS\/BRAF mutations potent prognostic and\/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem. 2012;12:163\u201371.","journal-title":"Anticancer Agents Med Chem"},{"key":"981_CR97","doi-asserted-by":"publisher","first-page":"1610206","DOI":"10.3389\/pore.2022.1610206","volume":"28","author":"S Uchida","year":"2022","unstructured":"Uchida S, Kojima T, Sugino T. Frequency and clinicopathological characteristics of patients with KRAS\/BRAF double-mutant colorectal cancer: An in silico study. Pathol Oncol Res POR. 2022;28:1610206.","journal-title":"Pathol Oncol Res POR"},{"key":"981_CR98","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ol.2020.12302","volume":"21","author":"HT Nguyen","year":"2021","unstructured":"Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in vietnamese patients with colorectal cancer. Oncol Lett. 2021;21:41.","journal-title":"Oncol Lett"},{"key":"981_CR99","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:377\u201386.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"981_CR100","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/oncolo\/oyac179","volume":"27","author":"AC Diehl","year":"2022","unstructured":"Diehl AC, Hannan LM, Zhen DB, Coveler AL, King G, Cohen SA, et al. KRAS mutation variants and co-occurring PI3K pathway alterations impact survival for patients with pancreatic ductal adenocarcinomas. Oncologist. 2022;27:1025\u201333.","journal-title":"Oncologist"},{"key":"981_CR101","doi-asserted-by":"publisher","first-page":"100874","DOI":"10.1016\/j.tranon.2020.100874","volume":"13","author":"Q Luo","year":"2020","unstructured":"Luo Q, Chen D, Fan X, Fu X, Ma T, Chen D. KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report. Transl Oncol. 2020;13:100874.","journal-title":"Transl Oncol"},{"key":"981_CR102","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","volume":"25","author":"S Misale","year":"2019","unstructured":"Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:796\u2013807.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR103","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563\u201375.","journal-title":"Nat Rev Cancer"},{"key":"981_CR104","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-14-3112","volume":"21","author":"A Calles","year":"2015","unstructured":"Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:2851\u201360.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","volume":"21","author":"SA Kerk","year":"2021","unstructured":"Kerk SA, Papagiannakopoulos T, Shah YM, Lyssiotis CA. Metabolic networks in mutant KRAS-driven tumours: Tissue specificities and the microenvironment. Nat Rev Cancer. 2021;21:510\u201325.","journal-title":"Nat Rev Cancer"},{"key":"981_CR106","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822\u201335.","journal-title":"Cancer Discov"},{"key":"981_CR107","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ccell.2022.08.015","volume":"40","author":"S Kitajima","year":"2022","unstructured":"Kitajima S, Tani T, Springer BF, Campisi M, Osaki T, Haratani K, et al. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell. 2022;40:1128\u2013e11448.","journal-title":"Cancer Cell"},{"key":"981_CR108","doi-asserted-by":"publisher","first-page":"2392341","DOI":"10.1080\/15384047.2024.2392341","volume":"25","author":"H Shan","year":"2024","unstructured":"Shan H, Tian G, Zhang Y, Qiu Z. Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer. Cancer Biol Ther. 2024;25:2392341.","journal-title":"Cancer Biol Ther"},{"key":"981_CR109","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41374-020-00517-x","volume":"101","author":"Y Wang","year":"2021","unstructured":"Wang Y, Xue Q, Zheng Q, Jin Y, Shen X, Yang M, et al. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. Lab Investig J Tech Methods Pathol. 2021;101:463\u201376.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"981_CR110","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-24-2330","volume":"85","author":"EG Lloyd","year":"2025","unstructured":"Lloyd EG, Jihad M, Manansala JS, Li W, Cheng PSW, Mucciolo G, et al. SMAD4 and KRAS status shape cancer cell-stromal crosstalk and therapeutic response in pancreatic cancer. Cancer Res. 2025;85:1368\u201389.","journal-title":"Cancer Res"},{"key":"981_CR111","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2022.07.016","volume":"143","author":"IZM Kreuger","year":"2023","unstructured":"Kreuger IZM, Slieker RC, van Groningen T, van Doorn R. Therapeutic strategies for targeting CDKN2A loss in melanoma. J Invest Dermatol Elsevier. 2023;143:18\u2013e251.","journal-title":"J Invest Dermatol Elsevier"},{"key":"981_CR112","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/ijc.28619","volume":"134","author":"MRJ Kohonen-Corish","year":"2014","unstructured":"Kohonen-Corish MRJ, Tseung J, Chan C, Currey N, Dent OF, Clarke S, et al. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer. 2014;134:2820\u20138.","journal-title":"Int J Cancer"},{"key":"981_CR113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 2023;83:141\u201357.","journal-title":"Cancer Res"},{"key":"981_CR114","doi-asserted-by":"publisher","first-page":"1133472","DOI":"10.3389\/fcell.2023.1133472","volume":"11","author":"A Ragupathi","year":"2023","unstructured":"Ragupathi A, Singh M, Perez AM, Zhang D. Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Front Cell Dev Biol. 2023;11:1133472.","journal-title":"Front Cell Dev Biol"},{"key":"981_CR115","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/cancers13030575","volume":"13","author":"S Miklikova","year":"2021","unstructured":"Miklikova S, Trnkova L, Plava J, Bohac M, Kuniakova M, Cihova M. The role of BRCA1\/2-mutated tumor microenvironment in breast cancer. Cancers. 2021;13:575.","journal-title":"Cancers"},{"key":"981_CR116","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.3390\/ijms231810892","volume":"23","author":"K Gasimli","year":"2022","unstructured":"Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, et al. Sequential targeting of PLK1 and PARP1 reverses the resistance to PARP inhibitors and enhances platin-based chemotherapy in BRCA-deficient high-grade serous ovarian cancer with KRAS amplification. Int J Mol Sci. 2022;23:10892.","journal-title":"Int J Mol Sci"},{"key":"981_CR117","doi-asserted-by":"publisher","first-page":"22705","DOI":"10.1038\/s41598-025-07668-1","volume":"15","author":"H-L Jang","year":"2025","unstructured":"Jang H-L, Kim ST, Hong JY, Jang K-T, Heo J, Chon HJ, et al. L-ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. Sci Rep. 2025;15:22705.","journal-title":"Sci Rep"},{"key":"981_CR118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/beta-catenin signaling in development and disease. Cell. 2006;127:469\u201380.","journal-title":"Cell"},{"key":"981_CR119","first-page":"661","volume-title":"Identification of FAP locus genes from chromosome 5q21","author":"KW Kinzler","year":"1991","unstructured":"Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Volume 253. New York, N.Y.: Science; 1991. pp. 661\u20135."},{"key":"981_CR120","doi-asserted-by":"crossref","unstructured":"Fodde R. The APC gene in colorectal cancer. Eur J Cancer. Oxford, England: 1990;2002;38:867\u201371.","DOI":"10.1016\/S0959-8049(02)00040-0"},{"key":"981_CR121","first-page":"330","volume":"487","author":"DM Muzny","year":"2012","unstructured":"Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nat Nat Publishing Group. 2012;487:330\u20137.","journal-title":"Nat Nat Publishing Group"},{"key":"981_CR122","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/0008-5472.CAN-17-3303","volume":"78","author":"E Sakai","year":"2018","unstructured":"Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, et al. Combined mutation of apc, kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 2018;78:1334\u201346.","journal-title":"Cancer Res"},{"key":"981_CR123","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","volume":"13","author":"CC Wong","year":"2022","unstructured":"Wong CC, Wu J-L, Ji F, Kang W, Bian X, Chen H, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer. Nat Commun. 2022;13:3971.","journal-title":"Nat Commun"},{"key":"981_CR124","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","volume":"2","author":"W-J Jeong","year":"2018","unstructured":"Jeong W-J, Ro EJ, Choi K-Y. Interaction between wnt\/\u03b2-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of \u03b2-catenin and RAS by targeting the wnt\/\u03b2-catenin pathway. NPJ Precis Oncol. 2018;2:5.","journal-title":"NPJ Precis Oncol"},{"key":"981_CR125","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48:10\u20138.","journal-title":"Semin Oncol"},{"key":"981_CR126","doi-asserted-by":"publisher","first-page":"102842","DOI":"10.1016\/j.jbc.2022.102842","volume":"299","author":"W-H Chang","year":"2023","unstructured":"Chang W-H, Liu Y, Hammes EA, Bryant KL, Cerione RA, Antonyak MA. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member survivin. J Biol Chem. 2023;299:102842.","journal-title":"J Biol Chem"},{"key":"981_CR127","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15384047.2018.1504718","volume":"20","author":"RS Burmi","year":"2019","unstructured":"Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS. Combined inhibition of the PI3K\/mTOR\/MEK pathway induces bim\/mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biol Ther. 2019;20:21\u201330.","journal-title":"Cancer Biol Ther"},{"key":"981_CR128","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-23-0519","volume":"23","author":"MT Than","year":"2024","unstructured":"Than MT, O\u2019Hara M, Stanger BZ, Reiss KA. KRAS-driven tumorigenesis and KRAS-driven therapy in pancreatic adenocarcinoma. Mol Cancer Ther. 2024;23:1378\u201388.","journal-title":"Mol Cancer Ther"},{"key":"981_CR129","doi-asserted-by":"publisher","first-page":"104554","DOI":"10.1016\/j.critrevonc.2024.104554","volume":"205","author":"L Liguori","year":"2025","unstructured":"Liguori L, Salomone F, Viggiano A, Sabbatino F, Pepe S, Formisano L, et al. KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies. Crit Rev Oncol Hematol. 2025;205:104554.","journal-title":"Crit Rev Oncol Hematol"},{"key":"981_CR130","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.7150\/thno.73089","volume":"12","author":"W Chong","year":"2022","unstructured":"Chong W, Zhu X, Ren H, Ye C, Xu K, Wang Z, et al. Integrated multi-omics characterization of KRAS mutant colorectal cancer. Theranostics. 2022;12:5138\u201354.","journal-title":"Theranostics"},{"key":"981_CR131","doi-asserted-by":"publisher","first-page":"105306","DOI":"10.1016\/j.esmoop.2025.105306","volume":"10","author":"K Iida","year":"2025","unstructured":"Iida K, Matsui Y, Urabe Y, Muramatsu T, Matsuzaki J, Saito Y. Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers. ESMO Open. 2025;10:105306.","journal-title":"ESMO Open"},{"key":"981_CR132","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.12688\/f1000research.126337.1","volume":"11","author":"L Therachiyil","year":"2022","unstructured":"Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S. Role of RAS signaling in ovarian cancer. F1000Research. 2022;11:1253.","journal-title":"F1000Research"},{"key":"981_CR133","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00428-014-1566-x","volume":"464","author":"M Fu","year":"2014","unstructured":"Fu M, Zhang W, Shan L, Song J, Shang D, Ying J, et al. Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). Virchows Arch Int J Pathol. 2014;464:575\u201381.","journal-title":"Virchows Arch Int J Pathol"},{"key":"981_CR134","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656\u201370.","journal-title":"Cell"},{"key":"981_CR135","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41586-019-1832-9","volume":"576","author":"CR Amendola","year":"2019","unstructured":"Amendola CR, Mahaffey JP, Parker SJ, Ahearn IM, Chen W-C, Zhou M, et al. KRAS4A directly regulates hexokinase 1. Nature. 2019;576:482\u20136.","journal-title":"Nature"},{"key":"981_CR136","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","volume":"61","author":"X Li","year":"2016","unstructured":"Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, et al. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol Cell. 2016;61:705\u201319.","journal-title":"Mol Cell"},{"key":"981_CR137","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-19-1363","volume":"80","author":"S Mukhopadhyay","year":"2020","unstructured":"Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. 2020;80:1630\u201343.","journal-title":"Cancer Res"},{"key":"981_CR138","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101\u20135.","journal-title":"Nature"},{"key":"981_CR139","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1073\/pnas.1617709114","volume":"114","author":"AM Gouw","year":"2017","unstructured":"Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, et al. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A. 2017;114:4300\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR140","first-page":"10574","volume":"34","author":"CF Ruiz","year":"2020","unstructured":"Ruiz CF, Montal ED, Haley JA, Bott AJ, Haley JD. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC. FASEB J Off Publ Fed Am Soc Exp Biol. 2020;34:10574\u201389.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"981_CR141","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Ma Q, Zhang W, Wu K, Shi L. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24:14.","journal-title":"Mol Cancer"},{"key":"981_CR142","first-page":"51","volume":"16","author":"D Varshavi","year":"2020","unstructured":"Varshavi D, Varshavi D, McCarthy N, Veselkov K, Keun HC, Everett JR. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. Metabolomics Off J Metabolomic Soc. 2020;16:51.","journal-title":"Metabolomics Off J Metabolomic Soc"},{"key":"981_CR143","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41419-025-08101-1","volume":"16","author":"L Tian","year":"2025","unstructured":"Tian L, Li H, Cui H, Tang C, Zhao P, Wang X, et al. Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. Cell Death Dis. 2025;16:785.","journal-title":"Cell Death Dis"},{"key":"981_CR144","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cells11030398","volume":"11","author":"F Pereira","year":"2022","unstructured":"Pereira F, Ferreira A, Reis CA, Sousa MJ, Oliveira MJ, Preto A. KRAS as a modulator of the inflammatory tumor microenvironment: Therapeutic implications. Cells. 2022;11:398.","journal-title":"Cells"},{"key":"981_CR145","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gro\u00df O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11:5439.","journal-title":"Nat Commun"},{"key":"981_CR146","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083\u2013e10996.","journal-title":"Immunity"},{"key":"981_CR147","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1101\/gad.1549407","volume":"21","author":"B Ancrile","year":"2007","unstructured":"Ancrile B, Lim K-H, Counter CM. Oncogenic ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21:1714\u20139.","journal-title":"Genes Dev"},{"key":"981_CR148","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1038\/s41467-022-30392-7","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPAR\u03b4. Nat Commun. 2022;13:2665.","journal-title":"Nat Commun"},{"key":"981_CR149","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1073\/pnas.95.7.3609","volume":"95","author":"F Okada","year":"1998","unstructured":"Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, et al. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor\/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A. 1998;95:3609\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR150","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/0008-5472.CAN-15-2388","volume":"76","author":"GD Brooks","year":"2016","unstructured":"Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, et al. IL6 trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 2016;76:866\u201376.","journal-title":"Cancer Res"},{"key":"981_CR151","first-page":"84","volume":"45","author":"J Ma","year":"2026","unstructured":"Ma J, Xu X, Zhu J, Wang J, Wang L, Liu Y, et al. HOXA10 drives immune evasion in early lung adenocarcinoma by recruiting immunosuppressive macrophages via NF-\u03baB\/CCL2 signaling. J Exp Clin Cancer Res CR. 2026;45:84.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"981_CR152","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","volume":"14","author":"JM Bailey","year":"2008","unstructured":"Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:5995\u20136004.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR153","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-018-0806-0","volume":"17","author":"AC Mutgan","year":"2018","unstructured":"Mutgan AC, Besikcioglu HE, Wang S, Friess H, Ceyhan GO, Demir IE. Insulin\/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Mol Cancer. 2018;17:66.","journal-title":"Mol Cancer"},{"key":"981_CR154","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282\u2013301.","journal-title":"Cancer Discov"},{"key":"981_CR155","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kl\u00f6ppel G, et al. Stat3\/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer. Cancer Cell Elsevier. 2011;19:456\u201369.","journal-title":"Cancer Cell Elsevier"},{"key":"981_CR156","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR157","first-page":"9405","volume":"34","author":"M Awaji","year":"2020","unstructured":"Awaji M, Saxena S, Wu L, Prajapati DR, Purohit A, Varney ML, et al. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J Off Publ Fed Am Soc Exp Biol. 2020;34:9405\u201318.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"981_CR158","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1101\/gad.351037.123","volume":"37","author":"J Han","year":"2023","unstructured":"Han J, Xu J, Liu Y, Liang S, LaBella KA, Chakravarti D, et al. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. Genes Dev. 2023;37:818\u201328.","journal-title":"Genes Dev"},{"key":"981_CR159","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-025-03299-5","volume":"134","author":"X Wang","year":"2026","unstructured":"Wang X, Shinjo K, Kumegawa K, Maruyama R, Mii S, Shiraki Y, et al. Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer. Br J Cancer. 2026;134:577\u201388.","journal-title":"Br J Cancer"},{"key":"981_CR160","doi-asserted-by":"crossref","unstructured":"Cao M, Peng W, Cheng B, Wang R, Chen W, Liu L, et al. PPY-induced iCAFs cultivate an immunosuppressive microenvironment in pancreatic cancer. Adv Sci. Weinheim, Baden-Wurttemberg, Germany; 2025;12:e2413432.","DOI":"10.1002\/advs.202413432"},{"key":"981_CR161","doi-asserted-by":"publisher","first-page":"116058","DOI":"10.1016\/j.biopha.2023.116058","volume":"171","author":"M Xu","year":"2024","unstructured":"Xu M, Zhao X, Wen T, Qu X. Unveiling the role of KRAS in tumor immune microenvironment. Biomed Pharmacother. 2024;171:116058.","journal-title":"Biomed Pharmacother"},{"key":"981_CR162","doi-asserted-by":"crossref","unstructured":"Kh T, S L, A K-J, J J, H H, K G, et al. Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC. Cancer Discov. 2022;12:47\u201361.","DOI":"10.1158\/2159-8290.CD-21-0369"},{"key":"981_CR163","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1158\/0008-5472.CAN-16-1308","volume":"76","author":"MJ Allegrezza","year":"2016","unstructured":"Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Perales-Puchalt A, Nguyen JM, et al. Trametinib drives T-cell-dependent control of KRAS-mutated tumors by inhibiting pathological myelopoiesis. Cancer Res. 2016;76:6253\u201365.","journal-title":"Cancer Res"},{"key":"981_CR164","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcancer.2003.09.015","volume":"14","author":"PM Campbell","year":"2004","unstructured":"Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol. 2004;14:105\u201314.","journal-title":"Semin Cancer Biol"},{"key":"981_CR165","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/0008-5472.CAN-16-0938","volume":"77","author":"AB Keeton","year":"2017","unstructured":"Keeton AB, Salter EA, Piazza GA. The RAS-effector interaction as a drug target. Cancer Res. 2017;77:221\u20136.","journal-title":"Cancer Res"},{"key":"981_CR166","doi-asserted-by":"publisher","first-page":"584181","DOI":"10.3389\/fcell.2020.584181","volume":"8","author":"I Masi","year":"2020","unstructured":"Masi I, Caprara V, Bagnato A, Rosan\u00f2 L. Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. Front Cell Dev Biol. 2020;8:584181.","journal-title":"Front Cell Dev Biol"},{"key":"981_CR167","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/cells11101645","volume":"11","author":"DS Richardson","year":"2022","unstructured":"Richardson DS, Spehar JM, Han DT, Chakravarthy PA, Sizemore ST. The RAL Enigma: Distinct Roles of RALA and RALB in Cancer. Cells. 2022;11:1645.","journal-title":"Cells"},{"key":"981_CR168","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1101\/gad.293449.116","volume":"31","author":"AT Boutin","year":"2017","unstructured":"Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, et al. Oncogenic kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017;31:370\u201382.","journal-title":"Genes Dev"},{"key":"981_CR169","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/1541-7786.MCR-21-0994","volume":"20","author":"S-H Choi","year":"2022","unstructured":"Choi S-H, Kim JK, Chen C-T, Wu C, Marco MR, Barriga FM, et al. KRAS mutants upregulate integrin \u03b24 to promote invasion and metastasis in colorectal cancer. Mol Cancer Res MCR. 2022;20:1305\u201319.","journal-title":"Mol Cancer Res MCR"},{"key":"981_CR170","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","volume":"97","author":"M Saitoh","year":"2023","unstructured":"Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. Semin Cancer Biol. 2023;97:21\u20139.","journal-title":"Semin Cancer Biol"},{"key":"981_CR171","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3389\/fonc.2019.01049","volume":"9","author":"EN Arner","year":"2019","unstructured":"Arner EN, Du W, Brekken RA. Behind the wheel of epithelial plasticity in KRAS-driven cancers. Front Oncol. 2019;9:1049.","journal-title":"Front Oncol"},{"key":"981_CR172","first-page":"464","volume":"29","author":"P Alamo","year":"2015","unstructured":"Alamo P, Gallardo A, Di Nicolantonio F, Pav\u00f3n MA, Casanova I, Trias M, et al. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB J Off Publ Fed Am Soc Exp Biol. 2015;29:464\u201376.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"981_CR173","first-page":"6679","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem Am Chem Soc. 2020;63:6679\u201393.","journal-title":"J Med Chem Am Chem Soc"},{"key":"981_CR174","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li L-S, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172:578\u2013e58917.","journal-title":"Cell"},{"key":"981_CR175","doi-asserted-by":"publisher","first-page":"115212","DOI":"10.1016\/j.ejmech.2023.115212","volume":"250","author":"Z Orgov\u00e1n","year":"2023","unstructured":"Orgov\u00e1n Z, P\u00e9czka N, Petri L, \u00c1br\u00e1nyi-Balogh P, Ran\u0111elovi\u0107 I, T\u00f3th S, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023;250:115212.","journal-title":"Eur J Med Chem"},{"key":"981_CR176","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","volume":"43","author":"J Feng","year":"2025","unstructured":"Feng J, Xiao X, Xia X, Min J, Tang W, Shi X, et al. A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer Cell. 2025;43:1866\u2013e188412.","journal-title":"Cancer Cell"},{"key":"981_CR177","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","volume":"27","author":"K-A Monaco","year":"2021","unstructured":"Monaco K-A, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, et al. LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27:2061\u201373.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR178","doi-asserted-by":"publisher","first-page":"e39677","DOI":"10.1016\/j.heliyon.2024.e39677","volume":"10","author":"AWY Chai","year":"2024","unstructured":"Chai AWY, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC. TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma. Heliyon. 2024;10:e39677.","journal-title":"Heliyon"},{"key":"981_CR179","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142\u201357.","journal-title":"Cancer Discov"},{"key":"981_CR180","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Han J, Hsu W-H, LaBella KA, Deng P, Shang X, et al. Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov. 2025;15:162\u201378.","journal-title":"Cancer Discov"},{"key":"981_CR181","doi-asserted-by":"publisher","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","volume":"14","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS. KRAS G12C inhibitor combination therapies: Current evidence and challenge. Front Oncol. 2024;14:1380584.","journal-title":"Front Oncol"},{"key":"981_CR182","doi-asserted-by":"publisher","first-page":"e0248775","DOI":"10.1371\/journal.pone.0248775","volume":"16","author":"P Ye","year":"2021","unstructured":"Ye P, Cai P, Xie J, Wei Y. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis. PLoS ONE. 2021;16:e0248775.","journal-title":"PLoS ONE"},{"key":"981_CR183","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10142-024-01421-z","volume":"24","author":"F Morshedzadeh","year":"2024","unstructured":"Morshedzadeh F, Abbaszadegan MR, Peymani M, Mozaffari-Jovin S. KRAS mutations detection methodology: From RFLP to CRISPR\/cas based methods. Funct Integr Genomics. 2024;24:183.","journal-title":"Funct Integr Genomics"},{"key":"981_CR184","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fonc.2020.00290","volume":"10","author":"C Li","year":"2020","unstructured":"Li C, He Q, Liang H, Cheng B, Li J, Xiong S, et al. Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis. Front Oncol. 2020;10:290.","journal-title":"Front Oncol"},{"key":"981_CR185","first-page":"13","volume":"31","author":"A Harl\u00e9","year":"2026","unstructured":"Harl\u00e9 A, Gavoille C, Bouch\u00e9 O, Abdelghani MB, Plaza J, Spaeth D, et al. Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study. Oncol Lett. 2026;31:13.","journal-title":"Oncol Lett"},{"key":"981_CR186","doi-asserted-by":"publisher","first-page":"e22930","DOI":"10.1002\/cncy.22930","volume":"133","author":"JB Iorgulescu","year":"2025","unstructured":"Iorgulescu JB, Yang RK, Roy-Chowdhuri S, Sura GH. Same-day molecular testing for targetable mutations in solid tumor cytopathology-the next frontier of the rapid on-site evaluation. Cancer Cytopathol. 2025;133:e22930.","journal-title":"Cancer Cytopathol"},{"key":"981_CR187","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/bios15050308","volume":"15","author":"P Lu","year":"2025","unstructured":"Lu P, Su X, Leong S, Xiu X, Song P, Peng J, et al. Analysis of colorectal cancer gene mutations and application of long blocker displacement amplification technology for high-throughput mutation detection. Biosensors. 2025;15:308.","journal-title":"Biosensors"},{"key":"981_CR188","doi-asserted-by":"publisher","first-page":"21241","DOI":"10.1038\/s41598-025-01884-5","volume":"15","author":"N Tamamura","year":"2025","unstructured":"Tamamura N, Hagiwara Y, Kato H, Ono Y, Takahashi K, Koyama K, et al. High dynamic range capillary electrophoresis method for sensitive detection of low-frequency driver mutations. Sci Rep. 2025;15:21241.","journal-title":"Sci Rep"},{"key":"981_CR189","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/mps8060142","volume":"8","author":"C Morimoto","year":"2025","unstructured":"Morimoto C, Hashimoto M. Fluorescence-based detection of KRAS mutations in genomic DNA using magnetic bead-coupled LDR assay. Methods Protoc. 2025;8:142.","journal-title":"Methods Protoc"},{"key":"981_CR190","doi-asserted-by":"crossref","unstructured":"Lee JY, Mun CW, Kim ER, Park S-G, Lee M-Y. Translational feasibility of a plasmonic microarray-based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer. NPJ Precis Oncol. 2026.","DOI":"10.1038\/s41698-026-01452-8"},{"key":"981_CR191","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.ctrv.2021.102309","volume":"101","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou S-HI. KRAS inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev. 2021;101:102309.","journal-title":"Cancer Treat Rev"},{"key":"981_CR192","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40164-023-00453-8","volume":"12","author":"F Batrash","year":"2023","unstructured":"Batrash F, Kutmah M, Zhang J. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC. Exp Hematol Oncol. 2023;12:93.","journal-title":"Exp Hematol Oncol"},{"key":"981_CR193","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2017.3438","volume":"317","author":"PA J\u00e4nne","year":"2017","unstructured":"J\u00e4nne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crin\u00f2 L, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA. 2017;317:1844\u201353.","journal-title":"JAMA"},{"key":"981_CR194","first-page":"27","volume":"41","author":"AK Kwan","year":"2022","unstructured":"Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: A comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res CR. 2022;41:27.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"981_CR195","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li L-S, Hansen R, Peters U, Kessler LV, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316\u201329.","journal-title":"Cancer Discov"},{"key":"981_CR196","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li L-S, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604\u20138.","journal-title":"Science"},{"key":"981_CR197","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1021\/acsmedchemlett.8b00311","volume":"9","author":"H Cheng","year":"2018","unstructured":"Cheng H, Planken S. Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. ACS Med Chem Lett Am Chem Soc. 2018;9:861\u20133.","journal-title":"ACS Med Chem Lett Am Chem Soc"},{"key":"981_CR198","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/oncolo\/oyab080","volume":"27","author":"J Wang","year":"2022","unstructured":"Wang J, Martin-Romano P, Cassier P, Johnson M, Haura E, Lenox L, et al. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation. Oncologist. 2022;27:536\u2013e553.","journal-title":"Oncologist"},{"key":"981_CR199","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63:52\u201365.","journal-title":"J Med Chem"},{"key":"981_CR200","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381.","journal-title":"N Engl J Med"},{"key":"981_CR201","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans A-MC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. Lancet Lond Engl. 2023;401:733\u201346.","journal-title":"Lancet Lond Engl"},{"key":"981_CR202","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1021\/acs.orglett.2c04266","volume":"25","author":"C-Y Chen","year":"2023","unstructured":"Chen C-Y, Lu Z, Scattolin T, Chen C, Gan Y, McLaughlin M. Synthesis of adagrasib (MRTX849), a covalent KRASG12C inhibitor drug for the treatment of cancer. Org Lett. 2023;25:944\u20139.","journal-title":"Org Lett"},{"key":"981_CR203","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med Mass Med Soc. 2022;387:120\u201331.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"981_CR204","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1021\/acschembio.4c00315","volume":"19","author":"R Mahran","year":"2024","unstructured":"Mahran R, Kapp JN, Valtonen S, Champagne A, Ning J, Gillette W, et al. Beyond KRAS(G12C): Biochemical and computational characterization of sotorasib and adagrasib binding specificity and the critical role of H95 and Y96. ACS Chem Biol. 2024;19:2152\u201364.","journal-title":"ACS Chem Biol"},{"key":"981_CR205","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med Mass Med Soc. 2021;384:2382\u201393.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"981_CR206","first-page":"3123","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem Am Chem Soc. 2022;65:3123\u201333.","journal-title":"J Med Chem Am Chem Soc"},{"key":"981_CR207","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, Li C, Luo L, Li X, Jia K, He N, et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024;42:1286\u2013e13008.","journal-title":"Cancer Cell"},{"key":"981_CR208","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1021\/acsmedchemlett.3c00478","volume":"15","author":"C Nilewski","year":"2024","unstructured":"Nilewski C, Labadie S, Wei B, Malhotra S, Do S, Gazzard L, et al. Structure-based design and evaluation of reversible KRAS G13D inhibitors. ACS Med Chem Lett. 2024;15:21\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"981_CR209","first-page":"19656","volume":"14","author":"O Jungholm","year":"2024","unstructured":"Jungholm O, Trkulja C, Moche M, Srinivasa SP, Christakopoulou M-N, Davidson M, et al. Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody. Sci Rep Nat Publishing Group. 2024;14:19656.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"981_CR210","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/acschembio.5c00249","volume":"20","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Shen T, Pampel J, Shokat KM. Distal covalent targeting suppresses signaling of oncogenic K-ras(G13C) in cancer cells. ACS Chem Biol Am Chem Soc. 2025;20:1696\u2013706.","journal-title":"ACS Chem Biol Am Chem Soc"},{"key":"981_CR211","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-025-02343-5","volume":"24","author":"S-Y Hwang","year":"2025","unstructured":"Hwang S-Y, Seo Y, Park S, Kim S-A, Moon I, Liu Y, et al. Targeting the HER2-ELF3-KRAS axis: A novel therapeutic strategy for KRASG13D colorectal cancer. Mol Cancer. 2025;24:139.","journal-title":"Mol Cancer"},{"key":"981_CR212","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1038\/s41467-021-26526-y","volume":"12","author":"T Gebregiworgis","year":"2021","unstructured":"Gebregiworgis T, Kano Y, St-Germain J, Radulovich N, Udaskin ML, Mentes A, et al. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nat Commun Nat Publishing Group. 2021;12:6274.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"981_CR213","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04451-4","volume":"603","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022;603:335\u201342.","journal-title":"Nature"},{"key":"981_CR214","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"981_CR215","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, B\u00f6ttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136.","journal-title":"Nature"},{"key":"981_CR216","doi-asserted-by":"crossref","unstructured":"Br\u00f6ker J, Waterson AG, Hodges TR, Abbott JR, Arnold A, B\u00f6ttcher J, et al. Discovery of BI-2493, a pan-KRAS inhibitor showing in vivo efficacy. J Med Chem 68:15649\u201368.","DOI":"10.1021\/acs.jmedchem.5c00576"},{"key":"981_CR217","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","volume":"68","author":"J Cregg","year":"2025","unstructured":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J Med Chem. 2025;68:6064\u201383.","journal-title":"J Med Chem"},{"key":"981_CR218","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2025","unstructured":"Filis P, Salgkamis D, Matikas A, Zerdes I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today. 2025;30:104250.","journal-title":"Drug Discov Today"},{"key":"981_CR219","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427\u201330.","journal-title":"Nature"},{"key":"981_CR220","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1021\/acs.jcim.3c00014","volume":"63","author":"A Romany","year":"2023","unstructured":"Romany A, Liu R, Zhan S, Clayton J, Shen J. Analysis of the ERK pathway cysteinome for targeted covalent inhibition of RAF and MEK kinases. J Chem Inf Model. 2023;63:2483\u201394.","journal-title":"J Chem Inf Model"},{"key":"981_CR221","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","volume":"594","author":"I Yen","year":"2021","unstructured":"Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021;594:418\u201323.","journal-title":"Nature"},{"key":"981_CR222","first-page":"113458","volume":"196","author":"F Janku","year":"2024","unstructured":"Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer Oxf Engl 1990. 2024;196:113458.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"981_CR223","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s10637-011-9687-4","volume":"30","author":"G Bodoky","year":"2012","unstructured":"Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30:1216\u201323.","journal-title":"Invest New Drugs"},{"key":"981_CR224","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-010-9392-8","volume":"29","author":"J Bennouna","year":"2011","unstructured":"Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. 2011;29:1021\u20138.","journal-title":"Invest New Drugs"},{"key":"981_CR225","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/JTO.0b013e3181e8b3a3","volume":"5","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5:1630\u20136.","journal-title":"J Thorac Oncol"},{"key":"981_CR226","doi-asserted-by":"publisher","first-page":"100920","DOI":"10.1016\/j.tranon.2020.100920","volume":"14","author":"M Xia","year":"2020","unstructured":"Xia M, Li X, Diao Y, Du B, Li Y. Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. Transl Oncol. 2020;14:100920.","journal-title":"Transl Oncol"},{"key":"981_CR227","first-page":"189","volume":"10","author":"D-Y Ruan","year":"2025","unstructured":"Ruan D-Y, Wu H-X, Xu Y, Munster PN, Deng Y, Richardson G, et al. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal Transduct Target Ther. Nat Publishing Group. 2025;10:189.","journal-title":"Nat Publishing Group"},{"key":"981_CR228","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol OncolJ Hematol Oncol. 2020;13:50.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"981_CR229","doi-asserted-by":"crossref","unstructured":"Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, et al. Targeting cancer with small-molecule pan-KRAS degraders. Science. American Association for the Advancement of Science. 2024;385:1338\u201347.","DOI":"10.1126\/science.adm8684"},{"key":"981_CR230","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","volume":"6","author":"MJ Bond","year":"2020","unstructured":"Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs. ACS Cent Sci. 2020;6:1367\u201375.","journal-title":"ACS Cent Sci"},{"key":"981_CR231","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","volume":"67","author":"C Zhou","year":"2024","unstructured":"Zhou C, Fan Z, Gu Y, Ge Z, Tao Z, Cui R, et al. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D. J Med Chem. 2024;67:1147\u201367.","journal-title":"J Med Chem"},{"key":"981_CR232","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","volume":"85","author":"Z Luo","year":"2025","unstructured":"Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, et al. Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR\u2013ABL\u2013positive leukemia. Cancer Res. 2025;85:101\u201317.","journal-title":"Cancer Res"},{"key":"981_CR233","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","volume":"67","author":"Y Lv","year":"2024","unstructured":"Lv Y, Yang Z, Chen Y, Ma X, Guo M, Zhang C, et al. A potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRASG12C inhibitor. J Med Chem. 2024;67:2487\u2013511.","journal-title":"J Med Chem"},{"key":"981_CR234","doi-asserted-by":"publisher","first-page":"114088","DOI":"10.1016\/j.ejmech.2021.114088","volume":"230","author":"F Yang","year":"2022","unstructured":"Yang F, Wen Y, Wang C, Zhou Y, Zhou Y, Zhang Z-M, et al. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. Eur J Med Chem. 2022;230:114088.","journal-title":"Eur J Med Chem"},{"key":"981_CR235","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","volume":"8","author":"T Yoshinari","year":"2025","unstructured":"Yoshinari T, Nagashima T, Ishioka H, Inamura K, Nishizono Y, Tasaki M, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8:254.","journal-title":"Commun Chem"},{"key":"981_CR236","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","volume":"68","author":"X Ji","year":"2025","unstructured":"Ji X, Li H, Wu G, Zhang Q, He X, Wu Y, et al. Discovery and characterization of RP03707: A highly potent and selective KRASG12D PROTAC. J Med Chem. 2025;68:10238\u201354.","journal-title":"J Med Chem"},{"key":"981_CR237","doi-asserted-by":"publisher","first-page":"118635","DOI":"10.1016\/j.ejmech.2026.118635","volume":"307","author":"H Yim","year":"2026","unstructured":"Yim H, Song X, Zhong Y, Hu J, Xiong Y, Jin J. Discovery of KRAS-G12D degraders via exploration of various E3 ligases. Eur J Med Chem. 2026;307:118635.","journal-title":"Eur J Med Chem"},{"key":"981_CR238","doi-asserted-by":"publisher","first-page":"20103","DOI":"10.1021\/acs.jmedchem.5c01034","volume":"68","author":"Z Liu","year":"2025","unstructured":"Liu Z, Zheng H, Tian Y, Li Z, Zhang S, Zhang S, et al. ZJK-807: A selective PROTAC degrader of KRASG12D overcoming resistance in pancreatic cancer. J Med Chem. 2025;68:20103\u201329.","journal-title":"J Med Chem"},{"key":"981_CR239","doi-asserted-by":"crossref","unstructured":"Vetma V, Puoti I, Karolak N, Chakraborti S, Diers E, Girardi E, et al. Identification of a highly cooperative PROTAC degrader targeting GTP-loaded KRAS(on) alleles. J Am Chem Soc. 2025;147:41367\u2013378.","DOI":"10.1021\/jacs.5c10354"},{"key":"981_CR240","doi-asserted-by":"publisher","first-page":"16938","DOI":"10.1073\/pnas.2000312117","volume":"117","author":"V Vidimar","year":"2020","unstructured":"Vidimar V, Beilhartz GL, Park M, Biancucci M, Kieffer MB, Gius DR, et al. An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth. Proc Natl Acad Sci U S A. 2020;117:16938\u201348.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR241","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/toxins9090291","volume":"9","author":"G Hall","year":"2017","unstructured":"Hall G, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxin therapeutics: Beyond neutralization. Toxins. 2017;9:291.","journal-title":"Toxins"},{"key":"981_CR242","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3389\/fmicb.2019.02340","volume":"10","author":"F Shafiee","year":"2019","unstructured":"Shafiee F, Aucoin MG, Jahanian-Najafabadi A. Targeted diphtheria toxin-based therapy: A review article. Front Microbiol. 2019;10:2340.","journal-title":"Front Microbiol"},{"key":"981_CR243","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/toxins5081486","volume":"5","author":"A Antignani","year":"2013","unstructured":"Antignani A, FitzGerald D, Immunotoxins. The role of the toxin \u2020. Toxins. 2013;5:1486\u2013502.","journal-title":"Toxins"},{"key":"981_CR244","doi-asserted-by":"publisher","first-page":"110272","DOI":"10.1016\/j.compbiomed.2025.110272","volume":"192","author":"J Saetang","year":"2025","unstructured":"Saetang J, Yamabhai M, Rangnoi K, Prompat N, Haewphet T, Sangkhathat S, et al. Identification and characterization of oncogenic KRAS G12V inhibitory peptides by phage display, molecular docking and molecular dynamic simulation. Comput Biol Med. 2025;192:110272.","journal-title":"Comput Biol Med"},{"key":"981_CR245","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acscentsci.0c00514","volume":"6","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Gao R, Hu Q, Peacock H, Peacock DM, Dai S, et al. GTP-state-selective cyclic peptide ligands of K-ras(G12D) block its interaction with raf. ACS Cent Sci Am Chem Soc. 2020;6:1753\u201361.","journal-title":"ACS Cent Sci Am Chem Soc"},{"key":"981_CR246","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.adn4955","volume":"386","author":"M-G Alameh","year":"2024","unstructured":"Alameh M-G, Semon A, Bayard NU, Pan Y-G, Dwivedi G, Knox J, et al. A multivalent mRNA-LNP vaccine protects against clostridioides difficile infection. Science. 2024;386:69\u201375.","journal-title":"Science"},{"key":"981_CR247","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24:2700.","journal-title":"Int J Mol Sci"},{"key":"981_CR248","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023;13:e1384.","journal-title":"Clin Transl Med"},{"key":"981_CR249","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41422-024-00990-9","volume":"34","author":"X Wang","year":"2024","unstructured":"Wang X, Wang W, Zou S, Xu Z, Cao D, Zhang S, et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: Clinical benefit in patients with advanced solid tumors. Cell Res. 2024;34:661\u20134.","journal-title":"Cell Res"},{"key":"981_CR250","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met \u00d6, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450\u20138.","journal-title":"Lancet Oncol"},{"key":"981_CR251","doi-asserted-by":"publisher","first-page":"217752","DOI":"10.1016\/j.canlet.2025.217752","volume":"625","author":"H Li","year":"2025","unstructured":"Li H, Min L, Du H, Wei X, Tong A. Cancer mRNA vaccines: Clinical application progress and challenges. Cancer Lett. 2025;625:217752.","journal-title":"Cancer Lett"},{"key":"981_CR252","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"981_CR253","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/s41467-023-39571-6","volume":"14","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Peng Y, Ji F, Chen H, Kang W, Chan L-S, et al. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer. Nat Commun. 2023;14:4677.","journal-title":"Nat Commun"},{"key":"981_CR254","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","volume":"13","author":"A Poole","year":"2022","unstructured":"Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, et al. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nat Commun Nat Publishing Group. 2022;13:5333.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"981_CR255","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun Nat Publishing Group. 2023;14:6389.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"981_CR256","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","volume":"22","author":"X Chi","year":"2017","unstructured":"Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today. 2017;22:823\u201333.","journal-title":"Drug Discov Today"},{"key":"981_CR257","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","volume":"357","author":"S Anthiya","year":"2023","unstructured":"Anthiya S, \u00d6zt\u00fcrk SC, Yanik H, Tavukcuoglu E, \u015eahin A, Datta D, et al. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release Off J Control Release Soc. 2023;357:67\u201383.","journal-title":"J Control Release Off J Control Release Soc"},{"key":"981_CR258","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12029-021-00667-1","volume":"53","author":"S Kamran","year":"2022","unstructured":"Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, Shekari N, et al. Combination therapy with KRAS and P38\u03b1 siRNA suppresses colorectal cancer growth and development in SW480 cell line. J Gastrointest Cancer. 2022;53:597\u2013604.","journal-title":"J Gastrointest Cancer"},{"key":"981_CR259","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtn.2023.07.027","volume":"33","author":"L Yang","year":"2023","unstructured":"Yang L, Li Z, Binzel DW, Guo P, Williams TM. Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles. Mol Ther Nucleic Acids. 2023;33:559\u201371.","journal-title":"Mol Ther Nucleic Acids"},{"key":"981_CR260","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","volume":"32","author":"M Moazzam","year":"2024","unstructured":"Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther J Am Soc Gene Ther. 2024;32:284\u2013312.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"981_CR261","doi-asserted-by":"publisher","first-page":"1303304","DOI":"10.3389\/fimmu.2023.1303304","volume":"14","author":"RA Mariuzza","year":"2023","unstructured":"Mariuzza RA, Wu D, Pierce BG. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity. Front Immunol. 2023;14:1303304.","journal-title":"Front Immunol"},{"key":"981_CR262","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/imr.13233","volume":"320","author":"M Malviya","year":"2023","unstructured":"Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, et al. Challenges and solutions for therapeutic TCR-based agents. Immunol Rev. 2023;320:58\u201382.","journal-title":"Immunol Rev"},{"key":"981_CR263","doi-asserted-by":"publisher","first-page":"e1049803","DOI":"10.1080\/2162402X.2015.1049803","volume":"5","author":"L Dubrovsky","year":"2016","unstructured":"Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, et al. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 2016;5:e1049803.","journal-title":"Oncoimmunology"},{"key":"981_CR264","doi-asserted-by":"crossref","unstructured":"Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C et al. Targeting mutated KRAS by HLA-a*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. J Mol Med. Berlin, Germany; 2025;103:1231\u201346.","DOI":"10.1007\/s00109-025-02585-2"},{"key":"981_CR265","first-page":"777","volume":"15","author":"Y Shen","year":"2020","unstructured":"Shen Y, Wei X, Jin S, Wu Y, Zhao W, Xu Y, et al. TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation. Asian J Pharm Sci. 2020;15:777\u201385.","journal-title":"Asian J Pharm Sci"},{"key":"981_CR266","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","volume":"16","author":"AY Chang","year":"2016","unstructured":"Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, et al. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther. 2016;16:979\u201387.","journal-title":"Expert Opin Biol Ther"},{"key":"981_CR267","first-page":"eadd8643","volume-title":"CRISPR technology: A decade of genome editing is only the beginning","author":"JY Wang","year":"2023","unstructured":"Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Volume 379. New York, N.Y.: Science; 2023. p. eadd8643."},{"key":"981_CR268","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505\u201329.","journal-title":"Annu Rev Biophys"},{"key":"981_CR269","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee S-S, Chakraborty C. CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases. Mol Ther J Am Soc Gene Ther. 2021;29:571\u201386.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"981_CR270","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","volume":"447","author":"M Chen","year":"2019","unstructured":"Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett. 2019;447:48\u201355.","journal-title":"Cancer Lett"},{"key":"981_CR271","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-021-00772-0","volume":"28","author":"G Bender","year":"2021","unstructured":"Bender G, Fahrioglu Yamaci R, Taneri B. CRISPR and KRAS: A match yet to be made. J Biomed Sci. 2021;28:77.","journal-title":"J Biomed Sci"},{"key":"981_CR272","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12672-025-02231-w","volume":"16","author":"HT Hashim","year":"2025","unstructured":"Hashim HT, Alhatemi AQM, Fatima T, Haque T, Sulaiman FA, Ganim M, et al. Efficacy of CRISPR-Cas9 gene editing for targeting KRAS mutations in pancreatic cancer: A systematic review. Discov Oncol. 2025;16:596.","journal-title":"Discov Oncol"},{"key":"981_CR273","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-23-2627","volume":"84","author":"J Boumelha","year":"2024","unstructured":"Boumelha J, de Castro A, Bah N, Cha H, de Carn\u00e9 Tr\u00e9cesson S, Rana S, et al. CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer Res. 2024;84:2231\u201346.","journal-title":"Cancer Res"},{"key":"981_CR274","doi-asserted-by":"publisher","first-page":"11879","DOI":"10.1038\/s41598-018-30205-2","volume":"8","author":"W Lee","year":"2018","unstructured":"Lee W, Lee JH, Jun S, Lee JH, Bang D. Selective targeting of KRAS oncogenic alleles by CRISPR\/Cas9 inhibits proliferation of cancer cells. Sci Rep. 2018;8:11879.","journal-title":"Sci Rep"},{"key":"981_CR275","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.3390\/ijms20225706","volume":"20","author":"E Lentsch","year":"2019","unstructured":"Lentsch E, Li L, Pfeffer S, Ekici AB, Taher L, Pilarsky C, et al. CRISPR\/Cas9-mediated knock-out of KrasG12D mutated pancreatic cancer cell lines. Int J Mol Sci. 2019;20:5706.","journal-title":"Int J Mol Sci"},{"key":"981_CR276","first-page":"681","volume":"6","author":"G Jang","year":"2023","unstructured":"Jang G, Kweon J, Kim Y. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Commun Biol Nat Publishing Group. 2023;6:681.","journal-title":"Commun Biol Nat Publishing Group"},{"key":"981_CR277","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.3390\/ijms20194687","volume":"20","author":"F Ingenito","year":"2019","unstructured":"Ingenito F, Roscigno G, Affinito A, Nuzzo S, Scognamiglio I, Quintavalle C, et al. The role of exo-miRNAs in cancer: A focus on therapeutic and diagnostic applications. Int J Mol Sci. 2019;20:4687.","journal-title":"Int J Mol Sci"},{"key":"981_CR278","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7150\/thno.21945","volume":"8","author":"C He","year":"2018","unstructured":"He C, Zheng S, Luo Y, Wang B. Exosome theranostics: Biology and translational medicine. Theranostics. 2018;8:237\u201355.","journal-title":"Theranostics"},{"key":"981_CR279","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: A phase I study with immunological correlates. Nat Commun. 2025;16:8696.","journal-title":"Nat Commun"},{"key":"981_CR280","doi-asserted-by":"publisher","first-page":"101732","DOI":"10.1016\/j.mtbio.2025.101732","volume":"32","author":"Y Xiang","year":"2025","unstructured":"Xiang Y, Liu Q, Liu K, Chen L, Chen F, Li T, et al. An exosome-based nanoplatform for siRNA delivery combined with starvation therapy promotes tumor cell death through autophagy, overcoming refractory KRAS-mutated tumors and restoring cetuximab chemosensitivity. Mater Today Bio. 2025;32:101732.","journal-title":"Mater Today Bio"},{"key":"981_CR281","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1080\/07388551.2020.1805406","volume":"40","author":"D Jafari","year":"2020","unstructured":"Jafari D, Malih S, Eini M, Jafari R, Gholipourmalekabadi M, Sadeghizadeh M, et al. Improvement, scaling-up, and downstream analysis of exosome production. Crit Rev Biotechnol. 2020;40:1098\u2013112.","journal-title":"Crit Rev Biotechnol"},{"key":"981_CR282","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","volume":"24","author":"J Li","year":"2025","unstructured":"Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: Progress and challenges. Mol Cancer. 2025;24:13.","journal-title":"Mol Cancer"},{"key":"981_CR283","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39:110993.","journal-title":"Cell Rep"},{"key":"981_CR284","doi-asserted-by":"publisher","first-page":"216264","DOI":"10.1016\/j.canlet.2023.216264","volume":"567","author":"N Hondo","year":"2023","unstructured":"Hondo N, Kitazawa M, Koyama M, Nakamura S, Tokumaru S, Miyazaki S, et al. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer Lett. 2023;567:216264.","journal-title":"Cancer Lett"},{"key":"981_CR285","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:1633\u201343.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"981_CR286","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.actbio.2025.12.049","volume":"212","author":"Y Ghanwatkar","year":"2026","unstructured":"Ghanwatkar Y, Mahto S, Chittipolu A, Ramanathan R, Shrestha P, Mahato RI. Dual inhibition of KRAS G12D and PI3K\/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer. Acta Biomater. 2026;212:637\u201354.","journal-title":"Acta Biomater"},{"key":"981_CR287","doi-asserted-by":"publisher","first-page":"e2319492121","DOI":"10.1073\/pnas.2319492121","volume":"121","author":"RA Jansen","year":"2024","unstructured":"Jansen RA, Mainardi S, Dias MH, Bosma A, van Dijk E, Selig R, et al. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Proc Natl Acad Sci U S A. 2024;121:e2319492121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"981_CR288","doi-asserted-by":"publisher","first-page":"8146","DOI":"10.1038\/s41467-024-52324-3","volume":"15","author":"P Anastasiou","year":"2024","unstructured":"Anastasiou P, Moore C, Rana S, Tomaschko M, Pillsbury CE, de Castro A, et al. Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade. Nat Commun. 2024;15:8146.","journal-title":"Nat Commun"},{"key":"981_CR289","first-page":"1321","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: Insights from in vitro experiments. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2021;16:1321\u201332.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"981_CR290","doi-asserted-by":"crossref","unstructured":"Guo Y, Zhong Y, Hu P, Chen Y, Guo W, Chen J, et al. Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer. Nat Commun. 2026.","DOI":"10.1038\/s41467-026-73805-7"},{"key":"981_CR291","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12935-025-03946-0","volume":"25","author":"Y Feng","year":"2025","unstructured":"Feng Y, Gan X, Rong X, Han Q. The components and regulation of the hippo pathway and its relationships with the progression and treatment of non-small cell lung cancer (NSCLC). Cancer Cell Int. 2025;25:309.","journal-title":"Cancer Cell Int"},{"key":"981_CR292","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther. 2022;29:875\u20138.","journal-title":"Cancer Gene Ther"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00981-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:05:25Z","timestamp":1788278725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00981-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":292,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00981-5","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The content of this manuscript has not been previously published and is not under consideration for publication elsewhere. All the authors agree with the content of the paper and with their being listed as co-authors.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}